IFNA1 and neoplasm: While CG0070 does this in a non-tumor-selective manner, resulting in an oncolytic mechanism of action, rAd-IFN/Syn-3 transduces cells in a non-tumor selectivemanner, leading to sustained high IFNα levels and a subsequent convenient quarterly treatment schedule with an excellent safety profile, where only 1.9% of the patients discontinued treatment.